Literature DB >> 18779937

Mitochondrial complex I subunits are altered in rats with neonatal ventral hippocampal damage but not in rats exposed to oxygen restriction at neonatal age.

Dorit Ben-Shachar1, Carmit Nadri, Rachel Karry, Galila Agam.   

Abstract

Several independent lines of evidence suggest mitochondrial dysfunction in schizophrenia in brain and periphery, including mitochondrial hypoplasia, dysfunction of the oxidative phosphorylation system, and altered mitochondrial-related gene expression. In an attempt to decipher whether mitochondrial complex I abnormality in schizophrenia is a core pathophysiological process or is attributable to medication, we studied two animal models of schizophrenia related to the neurodevelopmental hypothesis of this disorder. Protein levels of complex I subunits, 24, 51, and 75 kDa, were assessed in neonatal ventral hippocampal lesion rat model and in rats exposed to hypoxia at a neonatal age. In the prefrontal cortex, a major anatomical substrate of schizophrenia, neonatal ventral hippocampal lesion induced a significant prepubertal increase and postpubertal decrease in all three subunits of complex I as compared to sham-treated rats, while no change was observed in the cingulate cortex. Neonatal exposure to hypoxia did not affect protein levels of any of the three subunits in the prefrontal cortex. An age-dependent increase in the expression of complex I subunits was observed, which was distorted in the prefrontal cortex by the neonatal ventral hippocampal lesion. Complex I alterations in schizophrenia-related neurodevelopmental rat models appear to be brain region and animal model dependent. The results of this study support previous findings suggesting abnormal complex I expression as a pathological characteristic of schizophrenia rather than an effect of medication.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18779937     DOI: 10.1007/s12031-008-9144-9

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  13 in total

1.  Presynaptic mitochondria and the temporal pattern of neurotransmitter release.

Authors:  L Brodin; L Bakeeva; O Shupliakov
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-02-28       Impact factor: 6.237

Review 2.  The role of obstetric events in schizophrenia.

Authors:  Mary Catherine Clarke; Michelle Harley; Mary Cannon
Journal:  Schizophr Bull       Date:  2005-11-23       Impact factor: 9.306

3.  Energy thresholds in brain mitochondria. Potential involvement in neurodegeneration.

Authors:  G P Davey; S Peuchen; J B Clark
Journal:  J Biol Chem       Date:  1998-05-22       Impact factor: 5.157

4.  Translating developmental time across mammalian species.

Authors:  B Clancy; R B Darlington; B L Finlay
Journal:  Neuroscience       Date:  2001       Impact factor: 3.590

5.  Deficient hippocampal neuron expression of proteasome, ubiquitin, and mitochondrial genes in multiple schizophrenia cohorts.

Authors:  C Anthony Altar; Linda W Jurata; Vin Charles; Andrew Lemire; Peng Liu; Yury Bukhman; Theresa A Young; Jeff Bullard; Hiroko Yokoe; Maree J Webster; Michael B Knable; Jeffrey A Brockman
Journal:  Biol Psychiatry       Date:  2005-07-15       Impact factor: 13.382

Review 6.  Energy metabolism in mammalian brain during development.

Authors:  Maria Erecinska; Shobha Cherian; Ian A Silver
Journal:  Prog Neurobiol       Date:  2004-08       Impact factor: 11.685

7.  Mitochondrial DNA HV lineage increases the susceptibility to schizophrenia among Israeli Arabs.

Authors:  Shirly Amar; Alon Shamir; Ofer Ovadia; Monica Blanaru; Alon Reshef; Ilana Kremer; Marcella Rietschel; Thomas G Schulze; Wolfgang Maier; R H Belmaker; Richard P Ebstein; Galila Agam; Dan Mishmar
Journal:  Schizophr Res       Date:  2007-06-12       Impact factor: 4.939

8.  Decreased cytochrome-c oxidase activity and lack of age-related accumulation of mitochondrial DNA deletions in the brains of schizophrenics.

Authors:  L Cavelier; E E Jazin; I Eriksson; J Prince; U Båve; L Oreland; U Gyllensten
Journal:  Genomics       Date:  1995-09-01       Impact factor: 5.736

9.  State-dependent alterations in mitochondrial complex I activity in platelets: a potential peripheral marker for schizophrenia.

Authors:  N Dror; E Klein; R Karry; A Sheinkman; Z Kirsh; M Mazor; M Tzukerman; D Ben-Shachar
Journal:  Mol Psychiatry       Date:  2002       Impact factor: 15.992

Review 10.  Neonatal intermittent hypoxia impairs dopamine signaling and executive functioning.

Authors:  Michael J Decker; David B Rye
Journal:  Sleep Breath       Date:  2002-12       Impact factor: 2.816

View more
  6 in total

Review 1.  Mitochondrial dysfunction and pathology in bipolar disorder and schizophrenia.

Authors:  Hayley B Clay; Stephanie Sillivan; Christine Konradi
Journal:  Int J Dev Neurosci       Date:  2010-09-15       Impact factor: 2.457

Review 2.  Impaired mitochondrial function in psychiatric disorders.

Authors:  Husseini Manji; Tadafumi Kato; Nicholas A Di Prospero; Seth Ness; M Flint Beal; Michael Krams; Guang Chen
Journal:  Nat Rev Neurosci       Date:  2012-04-18       Impact factor: 34.870

Review 3.  Molecular links between mitochondrial dysfunctions and schizophrenia.

Authors:  Cana Park; Sang Ki Park
Journal:  Mol Cells       Date:  2012-02-15       Impact factor: 5.034

4.  Mitochondrial Dysfunction in Schizophrenia: Determination of Mitochondrial Respiratory Activity in a Two-Hit Mouse Model.

Authors:  Cécile Monpays; Jessica Deslauriers; Philippe Sarret; Sylvain Grignon
Journal:  J Mol Neurosci       Date:  2016-03-31       Impact factor: 3.444

5.  Mitochondrial complex I and III gene mRNA levels in schizophrenia, and their relationship with clinical features.

Authors:  Süleyman Akarsu; Deniz Torun; Abdullah Bolu; Murat Erdem; Salih Kozan; Mehmet Ak; Hatice Akar; Özcan Uzun
Journal:  J Mol Psychiatry       Date:  2014-12-10

6.  Neuroanatomical pattern of mitochondrial complex I pathology varies between schizophrenia, bipolar disorder and major depression.

Authors:  Dorit Ben-Shachar; Rachel Karry
Journal:  PLoS One       Date:  2008-11-07       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.